Jean-Marc BRONDELLO Ph.D life Science and cellular Biology

Course and current status

Jean-Marc Brondello studied Pharmacology and Cellular Biology at the University of Nice (France) and completed his PhD on biology and cell cycle regulation in Jacques Pouyssegur’s lab in Nice (France).

He then moved to California at The Scripps Research Institute (La jolla, USA) to perform a 4-year postdoctoral training in Paul Russell’s Lab working on DNA damage checkpoint and regulation

In 2002, he was nominated as Research Associate at INSERM and developed projects on DNA damage checkpoint regulation linked to cellular senescence and cancer at the Institute on Human Genetic (CNRS, Montpellier)

In 2005, he was the laureate of French-Canadian exchange program and was invited at the University of Montreal (Qc, Canada) for performing a high throughput screen on new checkpoint regulatory proteins.

In 2008, he jointed as research scientist the INSERM Unit directed by Christian Jorgensen at Montpellier (France), where he developed a new research project on the link between cellular senescence and osteoarticular diseases.

Since 2015, as member of the national INSERM consortium on aging studies: AGEMED, he is managing a research group entitled “innovative senotherapeutic strategies applied to osteoarticular diseases and Regenerative Medicine” at Institute for Regenerative Medicine and Biotherapy, IRMB, Montpellier, France.

Current address:

Institute For Regenerative Medicine and Biotherapy (IRMB) INSERM U1183

Group Leader "innovative senotherapies applied to osteoarticular diseases and regenerative medicine" Equipe 2

CHU St Eloi, 34295 Montpellier cedex 05, France

Research grants, fellowships and awards

2019-2021:  Comparative senescence phenotypes associated to Covid-19 (co-applicant)

2016-2023 : National INSERM consortium on aging AGEMED (co-laureate)

2020-2021:  Industrial grant "senoCure" (PI)

2019-2020 : Montpellier University initial grant : osteoarthritis therapies (PI)

2015-2017 : Industrial grant  « Senestem » (co-laureate)

2015-2018 : ANR « Mitostem » (co-laureate)

2014-2015 :  ITMO aging « Rejuvstem » (co-lauréate)

2013-2015 : Reserach grant Fondation de l’Avenir (PI)

2009-2012 : Regional Ph.D fellowship Université de Montpellier (co-laureate)

2008-2011 : Research grant FRM (co-laureate)

2005-2006 : french-canadian exchange program fellowship : IRSC-INSERM (PI)

2004-2007 : Grant Cancérople Grand Sud-Ouest (projet 3R) (PI)

2001-2003 : Research grant ARC (PI)

1999-2000: california Leukemia society post-doctoral fellowship (PI)

Teaching activities

2013-now : Molecular and protemic studies in Licence, Montpellier university

2015-now : senotherapies for elderly: Regenerative medicine diploma Montpellier university

2017-now: senotherapies and regenerative medicine: Master 2 Montpellier university

2011-now : Senescence and checkpoint Master 2 Pharmacy faculty, Montpellier

2011-now : Senescence and epigenetic Master 2 Cell biology, Montpellier University

2015-2018 : Cellular biology practice in Licence, Montpellier University

2007-2012 : Project management in Biology Master Biotin , Montpellier University

INSTITUTIONAL RESPONSIBILITIES 

  •  Responsibilities within the INSERM Unit

2015-now      Equipment Committee leader, IRMB, France

2008-2015     Organizer of the scientific lecture committee, INM, France

2008-2015     Gaz and CO2 network manager

  •  Responsibilities within the Montpellier scientific community

2011-now      Co-founder and animator of the Montpellier Aging Network

2014-now      Educational committee member at IUT, Montpellier University

2013-now      PhD and pharma D Thesis Jury Member (6 thesis defense)

2016-now      Ph. D Student committee member (5 thesis), Montpellier University

2017-now      Jury at University professional committee, Montpellier

2010-now      Master 2 student jury, Montpellier University

2014-now      Jury Member of the PhD Program Selection, Montpellier University, France 

2016             scientific committee member on the first regional Aging symposium

2011             Scienfic committee member for the french-american FABS on aging

2008             Executive organizer committee for 38th SFBBM annual meeting

  •  Responsibilities within the national and international scientific community

2020-now      Co-coordinator for innovative Senotherapy collaborative program, AGEMED

2020-now      Editor for Cells

2015-now      Grant per Reviewer for national and international institutions

2004-now      journal per reviewer for several journals

  •  Society Membership:

2017             French society for Rhumatology

2017             French society for Stem cell research

2016             International cellular Senescence Association

 

 

 

Scientific summary

Osteoarticular diseases including Osteoarthritis (OA) are the most common chronic degenerative pathologies having pejorative consequences on quality of life in elderly and has a huge impact on the public health costs. OA pathology is characterized by progressive cartilage alteration, osteophyte formation, sub-chondral bone sclerosis, and synovial inflammation. To date, no validated curative medical treatments are available for OA patients. New "symptomatic slow-acting drugs" such as glucosamine are used but they still lack evidence for efficiency on long-term structural articular remodeling. Therefore, OA still shows a huge unmet need while symptomatic painkiller treatments remain alternatives before prosthetic surgical joint replacement. To develop innovative treatments, we should decipher how OA-driven events could affect joint homeostasis. Remarkably recent works published by us and others have given new insights on the cellular mechanisms namely cellular senescence that could explain phenotypes accounting for OA development.

Accordingly, we found with others senescent cells expressing p16INK4a and p21cdkn1a in cartilage, synovial and fat pad tissues from OA mice and OA Elderly patients. However, during the course of the disease, it still remains to decipher which, when and how articular joint cell-types are becoming senescent in order to propose innovative specific senotherapies for cartilage regeneration. Using in vivo transgenic murine models for senescence detection and depletion altogether with in vitro 2D and 3D senescent conditions on osteoarticular cells, our group aims at:

  • identifying senescent articular joint cells that drive tissue degeneration
  • developing strategies to eliminate such cells in vitro and in vivo
  • restoring joint functions in elderly to delay prosthetic surgery
Image d’exemple